PureTech Ventures received FDA approval for its medicines on July 9, 2025. Raju Kucherlapati and Robert Langer were involved in the company's board.
1 report, 1 independent
Updated Jul 9
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
PureTech Ventures received FDA approval for its medicines on July 9, 2025. Raju Kucherlapati and Robert Langer were involved in the company's board.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
- FDA
-
PureTech Ventures
american company
Nothing else this week.
Related events
- Vance Thompson Vision advocated for standard product approval during an FDA committee meeting chaired by Michael X. Repka.
- FDA approved a medical device from Abbott and supported a PARADIGM study based on data from the Cleveland Clinic.
- InflaRx is seeking discussions with the FDA and collaborating with Staidson BioPharmaceuticals on clinical trials.
- FDA approval is the goal for product candidates from Daré Bioscience, Inc.
- Replimune Group received FDA accelerated approval, and Mestag Therapeutics appointed new board members, including Victor Sandor and Philip Astley-Sparke.
Coverage
Newest first; wire copies grouped- Business WirePureTech Announces Board Change BOSTON, July 08, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated